CGS 19755

Known as: CGS-19755 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1988-2016
05101519882016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1998
1998
Selfotel (CGS 19755), a competitive N-methyl-D-aspartate antagonist, is neuroprotective in experimental models of ischemic… (More)
Is this relevant?
Highly Cited
1995
Highly Cited
1995
BACKGROUND AND PURPOSE CGS 19755 is a competitive N-methyl-D-aspartate (NMDA) receptor antagonist that limits neuronal damage in… (More)
Is this relevant?
1995
1995
Hypothermia or a glutamate receptor antagonist may offer protection when used before or within seconds of an ischemic insult. In… (More)
Is this relevant?
1995
1995
The in vivo neuroprotective effect and brain levels of cis-4-phosphonomethyl-2-piperidine carboxylic acid (CGS 19755), a… (More)
Is this relevant?
1993
1993
The non-competitive N-methyl-D-aspartate (NMDA) antagonists MK-801, PCP and ketamine have recently been found to produce full… (More)
Is this relevant?
1991
1991
We report the effects of intravenous infusion of CGS-19755, a potent competitive N-methyl-D-aspartate (NMDA) antagonist, on local… (More)
Is this relevant?
1990
1990
We evaluated several doses of cis-4-(phosphonomethyl)-2-piperidine-carboxylic acid (CGS-19755), a potent competitive N-methyl-D… (More)
Is this relevant?
1989
1989
CGS 19755 (cis-4-phosphonomethyl-2-piperidine-carboxylic acid), a competitive antagonist at N-methyl-D-aspartate (NMDA… (More)
Is this relevant?
1988
1988
CGS 19755 (cis-4-phosphonomethyl-2-piperidine carboxylic acid) was found to be a potent, stereospecific inhibitor of N-methyl-D… (More)
Is this relevant?
1988
1988
N-Methyl-D-aspartate (NMDA) antagonists reduce ischemic brain damage and associated hypermotility. Two potent, selective and… (More)
Is this relevant?